drug
DANZITEN
Marketedupdated 3mo agoby Azurity Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(3)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 18, 2040
~13.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Feb 18, 2040formulationUS 10874671
- Feb 18, 2040formulationUS 10874671
- Feb 18, 2040formulationUS 11793809
- Feb 18, 2040formulationUS 11793809
- Feb 18, 2040formulationUS 12403140
- Feb 18, 2040formulationUS 12403140
News(1)
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 3mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that